Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma

(2019) Junyu Long et al.   EBioMedicine

Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures

(2019) Dongqiang Zeng et al.   Cancer Immunology Research

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma

(2019) Lorenza Rimassa et al.   CANCER TREATMENT REVIEWS

Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma

(2019) Man Liu et al.   GUT

Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome

(2019) Marwan Fakih et al.   JOURNAL OF CLINICAL INVESTIGATION

From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma

(2019) Yaojie Fu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

(2019) C. Langer et al.   Journal of Thoracic Oncology

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma

(2019) Wenli Li et al.   Frontiers in Oncology

KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment

(2019) Amy Lauren Cummings et al.   Translational Lung Cancer Research

T Cell Dysfunction in Cancer

(2018) Daniela S. Thommen et al.   CANCER CELL

TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma

(2018) Jerome Biton et al.   CLINICAL CANCER RESEARCH

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

(2018) Manish A. Shah et al.   CLINICAL CANCER RESEARCH

Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial

(2018) Qian Chen et al.   GUT

Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification

(2018) Yutaka Kurebayashi et al.   HEPATOLOGY

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

(2018) Ming Yi et al.   Molecular Cancer

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression

(2018) Qi Zhang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention

(2018) Zhenqiu Liu et al.   JOURNAL OF HEPATOLOGY

Personalized treatment of patients with very early hepatocellular carcinoma

(2017) Alessandro Vitale et al.   JOURNAL OF HEPATOLOGY

Global trends and predictions in hepatocellular carcinoma mortality

(2017) Paola Bertuccio et al.   JOURNAL OF HEPATOLOGY

Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon (IFN) Receptor 1 To Repress IFN/JAK/STAT Signaling

(2017) Junbo Chen et al.   JOURNAL OF VIROLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

(2017) Teresa Davoli et al.   SCIENCE

Hepatic Immune Microenvironment in Alcoholic and Nonalcoholic Liver Disease

(2017) Jin-Seok Byun et al.   Biomed Research International

Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies

(2016) A. K. S. Salama et al.   ANNALS OF ONCOLOGY

Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

(2016) R. Finn et al.   ANNALS OF ONCOLOGY

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis

(2016) Andrea Schietinger et al.   IMMUNITY

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

(2016) Michael D. Iglesia et al.   JNCI-Journal of the National Cancer Institute

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

(2016) Michael D. Iglesia et al.   JNCI-Journal of the National Cancer Institute

Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-κB signal cascade

(2015) Lili Lu et al.   CANCER LETTERS

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Feature Selection with theBorutaPackage

(2015) Miron B. Kursa et al.   Journal of Statistical Software

NbClust: AnRPackage for Determining the Relevant Number of Clusters in a Data Set

(2015) Malika Charrad et al.   Journal of Statistical Software

Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin

(2013) R. Remark et al.   CLINICAL CANCER RESEARCH

Inferring tumour purity and stromal and immune cell admixture from expression data

(2013) Kosuke Yoshihara et al.   Nature Communications

VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue

(2012) G. Christoffersson et al.   BLOOD

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Th17 cells: positive or negative role in tumor?

(2010) Yuqiang Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL